Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Allogene Therapeutics develops off-the-shelf CAR T cell therapies to treat cancer and autoimmune diseases.
Allogene Therapeutics is a biotech company trying to solve one of the biggest practical problems in a powerful new kind of cancer treatment. CAR T therapy works by engineering a patient's own immune cells to hunt down cancer, and it has produced remarkable results. But it is also painfully slow, expensive, and fragile: you have to collect a sick patient's cells, ship them to a lab, engineer them, grow them, and send them back weeks later. Allogene's bet is to make these cells in advance from healthy donors, so they sit on a shelf ready to go.
That approach is called an "allogeneic" therapy, and the prize is an off-the-shelf product. Instead of a custom batch built for one person, Allogene wants to manufacture large lots of donor-derived T cells and infuse them into many patients. If it works, treatment could start faster, cost less, and reach people who currently can't wait for a custom batch. The company's pipeline centers on these engineered cell products, led by its lead candidate, cemacabtagene ansegedleucel, aimed at a type of lymphoma. The business reality is that Allogene is a clinical-stage company: it earns essentially no product revenue yet and funds itself by raising capital and spending it on years of trials. The science is genuinely hard. The body's immune system tends to recognize donor cells as foreign and attack them, and the donor cells can attack the patient too, so Allogene has to engineer around both problems. It also competes with Gilead Sciences's Kite, which sells the approved custom-made CAR T therapies, and with other players racing toward off-the-shelf versions.
Allogene has had its scars. It was founded in 2017 by former Kite executives and raised a huge amount of money right out of the gate. Then, in 2020, a safety scare in a trial rattled investors and the stock, and later the company trimmed its pipeline and cut costs to focus on the most promising programs. The payoff, if it comes, hinges on whether its donor cells clear trials safely and effectively — and whether regulators ever approve a shelf-ready CAR T that could change how these therapies are delivered.
Saved answer · last researched 15 Nov 2026